ASH 2025 – J&J’s multiple myeloma juggling act | ApexOnco - Clinical Trials news and analysis

Johnson & Johnson’s MajesTEC‑3 trial showed Tecvayli (a BCMA T‑cell engager) plus Darzalex cut risk of progression or death by 83% versus Darzalex‑based control in second‑to‑fourth‑line multiple myeloma, with PFS curves separating and nearly plateauing—findings the NEJM authors say could reset survival expectations—while overall survival was significantly improved (HR 0.46) despite early crossover driven by infection‑related deaths (13 vs 4) that largely occurred before protocol changes to reinforce immune‑globulin and antimicrobial prophylaxis. J&J has filed the combo with the FDA (breakthrough designation, RTOR) and positions it as a community‑delivered alternative to the one‑off BCMA CAR‑T Carvykti (approved in second line), raising potential internal competition and commercial implications given 2024 sales of Carvykti $963m and Tecvayli $549m; however, the safety profile will need confirmation in real‑world practice.

Analysis

J&J’s MajesTEC-3 late‑breaking ASH data show Tecvayli (BCMA T‑cell engager) plus Darzalex reduced the risk of progression or death by 83% versus Darzalex‑based control in second‑to‑fourth‑line multiple myeloma, with PFS curves separating early and approaching a plateau; NEJM authors characterized the results as potentially resetting survival expectations in the disease. The company has filed the combo with the FDA under breakthrough designation and real‑time oncology review, positioning this regimen as a community‑delivered alternative to BCMA CAR‑T.

Safety is the principal caveat: infection‑related deaths occurred in 13 patients (5%) versus 4 (1%) in the control arm, but 12 of the 13 happened before a protocol amendment that added immune globulin and antimicrobial prophylaxis; only one infection death occurred after the amendment. Despite early crossover in OS curves, overall survival was statistically improved with a hazard ratio of 0.46, and investigators contend adverse events can be mitigated with established prophylaxis—an assertion that requires real‑world validation.

Commercial implications are material: if approved earlier, the combo could cannibalize Carvykti, which was approved for second‑line use in April 2024 and generated $963m in 2024 versus Tecvayli’s $549m. Access dynamics favor the combo given approximately 5,000 Darzalex‑using centers versus 128 Carvykti centers, so FDA label, payer coverage, and post‑amendment safety outcomes are the key near‑term catalysts to watch.

Key Decisions for Investors

• Consider modestly increasing exposure to JNJ to reflect the strong PFS and OS signals and RTOR filing, while keeping position size limited to regulatory binary risk
• Monitor post‑amendment infection and real‑world safety data closely; if infection rates remain elevated, implement hedges or reduce clinical‑risk exposure
• Revisit earnings and revenue models for Carvykti and Tecvayli to quantify potential cannibalization given the combo's community‑delivery advantage and center access differential
• Use FDA labeling, payer coverage updates, and initial real‑world safety reports as decision points for scaling positions rather than acting solely on trial headline data